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Memory CD8+ cytotoxic T lymphocytes (CTLs) can protect against viral reinfection.
However, the signals driving rapid memory CTL reactivation have remained ill-defined.
Viral infections can trigger the release of the alarmin interleukin-33 (IL-33) from
non-hematopoietic cells. IL-33 signals through its unique receptor ST2 to promote
primary effector expansion and activation of CTLs. Here, we show that the transcription
factor STAT4 regulated the expression of ST2 on CTLs in vitro and in vivo in primary
infections with lymphocytic choriomeningitis virus (LCMV). In the primary antiviral
response, IL-33 enhanced effector differentiation and antiviral cytokine production in
a CTL-intrinsic manner. Further, using sequential adoptive transfers of LCMV-specific
CD8+ T cells, we deciphered the IL-33 dependence of circulating memory CTLs at
various stages of their development. IL-33 was found dispensable for the formation
and maintenance of memory CTLs, and its absence during priming did not affect their
recall response. However, in line with the CTL-boosting role of IL-33 in primary LCMV
infections, circulating memory CTLs required IL-33 for efficient secondary expansion,
enhanced effector functions, and virus control upon challenge infection. Thus, beyond
their effector-promoting activity in primary immune reactions, innate alarmin signals
also drive memory T cell recall responses, which has implications for immunity to
recurrent diseases.
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INTRODUCTION
An efficient activation and differentiation of effector CD8+ cytotoxic T lymphocytes (CTLs) is
critical for the control of many viral infections. Once the infection is cleared, most effector cells
(∼95%) undergo apoptosis, while a long-lived population of memory cells survives (1). Thereafter,
those memory cells are maintained by cytokines that provide signals for survival and homeostatic
proliferation, most prominently IL-7 and IL-15 (2, 3). Upon viral challenge, memory CTLs are
superior to their naive precursors in controlling secondary infections. This feature is attributed to a
higher number of antigen-specific cells and a more rapid acquisition of effector functions upon
antigen reencounter (4). Naïve CD8+ T cells require costimulatory signals for antigen-specific
antiviral responses, while CD8+ memory T cells, at least in certain settings, can be reactivated
independently of costimulation (5–7). In addition, the demand for cytokines differs between
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primary infection and recall responses (8, 9). The dependency of
memory T cells on alarmin signals such as IL-33 has not, however,
been studied yet.
IL-33 is a member of the IL-1 cytokine family and is
constitutively expressed by endothelial and epithelial cells as well
as by fibroblastic reticular cells in secondary lymphoid organs
(10–12). Upon necrotic cell death, IL-33 is released, acting as an
early damage signal, an alarmin, which can be sensed by several
innate and adaptive immune cells (13–15). During infection
with lymphocytic choriomeningitis virus (LCMV), splenic IL-33
mRNA levels increase. IL-33 signals through its receptor ST2,
also known as T1 or IL-1 receptor-like-1 (IL-1RL1), on effector
CTLs, to enhance their activation and antiviral functionality (16).
So far, the role of IL-33 in T cell responses was mainly studied
during primary effector activation. To address its function during
memory formation, maintenance, and recall responses, we
performed adoptive transfers of LCMV-specific CTLs into either
IL-33-deficient or wild-type (WT) hosts, followed by LCMV
infection, secondary crisscross T-cell transfer, and reinfection.
This allowed us to assess the fate and challenge performance
of memory CTLs when deprived of IL-33 at various stages of
their development. We found that IL-33 is not required for
the formation and maintenance of memory CTLs. However,
it is critical for memory CTL re-expansion, efficient effector
differentiation, and viral control during secondary infection. This
finding emphasizes an unexpected role for alarmins as key drivers
of protection by memory CD8+ T cell populations.
MATERIALS AND METHODS
Mice
C57BL/6 (wild type, WT), Stat4−/− (17), Tbx21−/− (18),
Ifnar1−/− (19), Il12p40−/− (20), Ifngr1−/− (21), Il1rl1−/− (22),
and Stat1−/− (23) mice were all backcrossed to C57BL/6
background and were used for CD8+ T cell isolation and/or
in infection experiments. Transgenic mice expressing the P14-
TCR specific for LCMV-H-2Db (24) and CD45.1 as congenic
marker on a C57BL/6 background were used as organ donors for
the isolation of LCMV-specific CD8+ T cells. CD45.2-expressing
C57BL/6 and Il33−/− (25) mice were used as recipients in
adoptive cell transfer experiments. In vivo experiments were
performed with male and female mice at the age of 8–24 weeks.
For adoptive T cell transfer experiments, T cells from male or
female donor mice were transferred into male recipients to avoid
rejection. When female recipients were used, donor T cells were
derived from female mice. Animal protocols were performed in
accordance with the German law for animal protection and the
institutional guidelines of the Charité Berlin. All experiments
were approved by the Landesamt für Gesundheit und Soziales in
Berlin (LAGeSO, approval number G 0242/12).
Virus Production and Virus Titer
Determination
The LCMV-WE and LCMV-Clone 13 strains were propagated
on L929 or BHK-21 cells, respectively. Virus stocks and organ
samples were titrated by standard immunofocus assays on
MC57G cells (26). In brief, MC57G cells were plated with organ
homogenates or virus stock dilutions and subsequently overlaid
with 2% methylcellulose. After 48 h of incubation at 37◦C, the
confluent monolayer of cells was fixed with 4% formaldehyde,
permeabilized with 1% Triton X-100 (v/v) and stained with
antibodies against LCMV nucleoprotein (VL-4). After a
secondary staining step with peroxidase conjugated anti-rat IgG
antibody (Jackson), foci were developed by 20min incubation
with OPD substrate (0.1M Na2HPO4, 0.5M citric acid, 0.03%
H2O2, and 20mg o-phenylenediamine dihydrochloride).
Adoptive T Cell Transfer and Virus
Infections
Naive CD45.1+ P14 CD8+ T cells were purified by magnetic
cell sorting in a negative enrichment approach with biotin-
labeled antibodies against CD4 (RM4-5), CD11b (M1/70), CD11c
(HL3), CD25 (7D4), Gr-1 (RB6-8C5), and CD19 (1D3) in
combination with anti-biotin microbeads (Miltenyi Biotec). For
primary infections, 1.5 × 104 purified P14 cells were transferred
into either C57BL/6 or Il33−/− mice, which were subsequently
infected intravenously with a low dose (LD, 200 PFU) LCMV-
WE in 200 µl MEM. P14 cells were analyzed at day 6.5 post
infection. In the experiments presented in Figures 3–5, splenic
CD45.1+ P14 CD8+ cells were isolated at day 16 after infection
and FACS-sorted by depletion of CD4 (RM4-5), CD19 (1D3), and
CD45.2 (104). For kinetic analysis without challenge infection,
1.5×106 sorted CD45.1+ P14 CD8+ T cells were re-transferred
into either C57BL/6 or Il33−/− mice. For challenge infections,
1.5 × 104 P14 cells were re-transferred into C57BL/6 or Il33−/−
mice. After 65 days, recipients were infected intravenously with a
high dose (HD, 2 × 106 PFU) LCMV-Clone 13 in 200 µl MEM
and analyzed 6.5 days later.
Primary T Cell Cultures
Naive CD8+ CD62Lhi CD44− cells were sorted from pooled
spleen and lymph node cells on a FACS Aria II. T cells were
cultured in RPMI 1640+GlutaMax-I (Gibco) supplemented
with 10% (v/v) FCS (Gibco), penicillin (100 U/ml; Gibco),
streptomycin (100µg/ml; Gibco), and ß-mercaptoethanol
(50 ng/ml; Sigma) in the presence of APCs, antibodies against
CD3 (145-2C11) and CD28 (37.51), both at 2.5µg/ml, IL-2
(5 ng/ml), and anti-IL-4 (11B11, 10µg/ml). In addition, IL-12
(10 ng/ml), IFN-γ (10 ng/ml), IFN-α and -β (each at 250 U/ml),
or combinations thereof were added for effector differentiation.
When indicated, plate-bound anti-CD3 (5µg/ml) and anti-
CD28 (3µg/ml) were used without APCs. T cells were analyzed
at day 5 of culture.
Cell Isolation and Flow Cytometry
Single-cell suspensions of spleens were prepared by mechanical
disruption. For cell isolation from livers, mechanical disruption
was followed by digestion with Collagenase D (0.1 U/ml,
Roche) for 30min at 37◦C. Then, lymphocytes were isolated
using Histopaque-1083 and high-density centrifugation (400 g at
20◦C for 20min). When indicated, ex vivo-isolated lymphocytes
and in vitro-differentiated CD8+ T cells were stained with
antibodies against CD8 (53–6.7), CD45.1 (A20), CD62L (MEL-
14), CD44 (IM7), KLRG1 (2F1), IL-18R (BG/IL18RA), CXCR3
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(CXCR3-173), CD127 (A7R34), and PD-1 (J34). For flow-
cytometric detection of cell surface ST2, splenocytes were stained
with digoxigenin-coupled anti-mouse ST2 antibody (DJ8). For
detection, a PE-coupled anti-digoxigenin Fab antibody (Roche)
was used. To augment the PE signal, we performed two rounds of
amplification using the PE FASER Kit (Miltenyi Biotec). LCMV-
specific CD8T cell response to the dominant glycoprotein-
derived epitope GP33 was assessed by MHC class I tetramer
staining as described previously (16). Samples were acquired on a
FACS Canto II (BD), and analyzed with FlowJo (BD). Dead cells
and doublets were excluded by a combination of forward scatter
height and width gating and the usage of propidium iodide or a
LIVE/DEAD fixable dye (BioLegend).
Intracellular Cytokine and Transcription
Factor Staining
For cytokine detection, ex vivo isolated cells were restimulated
with GP33 peptide for 4 h with addition of brefeldin A (5µg/ml;
all from Sigma-Aldrich) at 30min, followed by surface staining
and fixation in 2% formaldehyde (Merck). Intracellular staining
was performed in PBS/0.2% BSA containing 0.05% saponin
(Sigma-Aldrich) with antibodies against IFN-γ (XMG1.2), IL-
2 (JES6-5H4), and TNF-α (MPG-XT22). T-bet and Eomes
protein amounts were analyzed using FoxP3 staining buffer
set (eBioscience) according to the manufacturer’s instructions.
Briefly, cells were stained for surface marker expression and
then fixed with 1x Fixation/Permeabilization buffer, followed by
intracellular staining with antibodies against T-bet (4B10) and
Eomes (Dan11mag) in 1x permeabilization buffer. Cells were
washed in 1x permeabilization buffer and analyzed.
Statistical Analysis
GraphPad Prism (v5.02 and v7) software was used for data
analysis. Statistical significance was determined by unpaired two-
tailed Student’s t-test and Mann-Whitney U test as indicated in
the figure legends. P = 0.01 to 0.05 was considered statistically
significant (∗), p = 0.001 to 0.01 as very significant (∗∗), and p <
0.001 as extremely significant (∗∗∗). n.s., not significant.
RESULTS
ST2 Expression by CD8+ T Cells in vitro
and in vivo Depends Largely on STAT4
IL-33 directly exerts its function on activated CD8+ T cells by
signaling through its receptor ST2 (16, 27). We analyzed the
ability of CD8+ T cells to express ST2 in the absence of various
transcription factors and cytokine signals that are involved in
CTL effector differentiation—STAT4, IL-12, T-bet, type-I and
type-II interferons, and STAT1. To assess this in vitro, we
analyzed ST2 frequencies ofWT, Stat4−/−, Tbx21−/−, Ifnar1−/−,
Ifngr1−/−, and Stat1−/− CTLs, which were differentiated in the
presence of IL-12.WhileWT, Ifnar1−/−, Ifngr1−/−, and Stat1−/−
CTLs showed comparable ST2 expression, it was reduced by half
in Tbx21−/− CTLs and absent in Stat4−/− CTLs (Figures 1A,B).
In line with this result, a lack of IL-12, which signals via
STAT4, drastically reduced the frequencies of ST2 expression.
IFN-γ or IFN-α/β without IL-12 was not sufficient to induce
substantial ST2 expression, and adding them to IL-12 during
differentiation did not further increase the frequencies of ST2+
cells (Figure 1C). Next, we addressed the effect of STAT4 and
IL-12 signals on ST2 expression by CTLs in vivo. We infected
WT, STAT4−/−, Il12p40−/−, and ST2-deficient Il1rl1−/− control
mice with 200 PFU LCMV-WE, an infection setting known to
result in unimpaired virus clearance in all of the aforementioned
gene-targeted mice (16, 28, 29). ST2 expression on circulating
CTLs was transient and peaked at day 8 after infection, coinciding
with the peak CTL response. Stat4−/− CD8+ T cells exhibited
weakest ST2 expression (Figures 1D,E). In conjunction with the
observation that T cell-intrinsic STAT4 signals were vital for ST2
expression in vitro (cf. Figure 1A), it seems likely that impaired
ST2 expression in vivo was also due to a T cell-intrinsic STAT4
deficiency. As effector frequencies (marked by CD62L down-
regulation) varied between the different genotypes (Figure 1E),
we used MHC class I tetramers to determine ST2 expression
on effector CTLs that were specific for the LCMV glycoprotein-
derived epitope GP33. Consistent with ST2 expression patterns
in the total CD8+ T cell population, only a very small proportion
of GP33-specific Stat4−/− T cells displayed ST2 expression, and
significantly reduced ST2 levels were also observed in CTLs from
Il12p40−/− mice (Figures 1F,G). These findings show that ST2
expression on CTLs depends largely on STAT4, both in vitro
and in vivo.
IL-33 Enhances CD8+ T Cell Activation and
Differentiation During a Primary Viral
Infection
To characterize the activation and differentiation states of
CD8+ T cells primed without IL-33 signals, we infected WT
and Il1rl1−/− mice with LCMV and analyzed their CTLs at
day 6.5 after infection. Already at this early time point, the
absence of IL-33 signaling impaired the expansion of the splenic
CD8+ T cell pool (Figure 2A) and consequently reduced the
frequency and absolute numbers of CD44high CD62Llow CTLs
(Figures 2B,C). Analysis of LCMV-specific T cells by tetramer
staining showed reduced numbers of GP33- and NP396-specific
CTLs in ST2-deficient mice (Figure 2D). Moreover, a lack of
IL-33 signaling reduced the frequency of KLRG1- and CXCR3-
expressing LCMV-specific CD8+ T cells, which reflects reduced
effector differentiation (Figure 2E). To demonstrate that reduced
CTL activation was due to direct sensing of IL-33 by CD8+
T cells and not due to indirect effects on other cell types,
we transferred Il1rl1−/− P14 and Il1rl1+/+ P14 cells into WT
mice and subsequently infected the recipients with LCMV. At
day 6.5 post infection, ST2-deficient P14 cells isolated from
spleen and lymph nodes showed a reduced expression of KLRG1
(Figure 2F). CXCR3 expression was significantly reduced on
Il1rl1−/− P14 cells isolated from lymph nodes (Figure 2G),
and CD127 expression was increased on these cells in spleen
and lymph nodes (Figure 2H). As both KLRG1 and CXCR3
expression are controlled by the transcription factor T-bet (30,
31) we assessed its expression level in the transferred P14 cells.
The absence of IL-33 signals significantly reduced T-bet levels
(Figure 2I). Likewise, IL-18R expression intensity was decreased
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FIGURE 1 | ST2 expression depends largely on STAT4 in CD8+ T cells in vitro and in vivo. (A,B) Naive CD8+ T cells from WT and Stat4−/−, Tbx21−/−, Ifnar1−/−,
Ifngr1−/−, Stat1−/−, and Il1rl1−/− mice were activated with soluble anti-CD3 and anti-CD28 plus APCs and differentiated into effector cells in vitro in the presence of
IL-12 for 5 days. Mean + SD of ST2 frequency normalized to WT levels (A) in two to three independent cultures and representative histograms of ST2 expression (B)
are shown (gray line: Il1rl1−/− control staining). (C) Expression of ST2 on CD8+ T cells after in vitro differentiation with different combinations of cytokines and
plate-bound antibodies against CD3 and CD28. Bars indicate the mean + SD of three independent cultures. (D–G) WT, Stat4−/−, Il12p40−/−, and Il1rl1−/− mice
were infected with a low dose (LD, 200 PFU) LCMV-WE. (D) Circulating CD8+ T cells were analyzed for ST2 expression. Symbols of the time course analyses
represent the mean ± SEM values of two experiments (n = 5 per experiment). P-values were calculated for day 6, 8, and 10 post infection (two-way ANOVA with
Bonferroni’s post-test). (E) Representative contour plots of ST2 and CD62L expression of CD8+ T cells at day 8 after infection. (F,G) Quantification and representative
contour plots of ST2+ GP33-tetramer+ CD8+ T cells on day 8 post infection. Bars indicate the mean + SD (n = 5). P-values were calculated with unpaired two-tailed
Student’s t-test (A,C,F). *P < 0.05 and ***P < 0.001.
(Figure 2J). Reduced CTL activation in the absence of ST2 was
also reflected by a lower expression intensity of IFN-γ per cell
(Figures 2K,L). In addition, we found reduced frequencies of
virus-specific, IFN-γ-producing CTLs, expressing IFN-γ alone or
in combination with TNF-α and IL-2 in Il1rl1−/− mice at 6.5
days post LCMV infection (Figures 2M,N). Taken together, our
data show that a lack of IL-33 signals leads to lower T-bet and
type-I cytokine expression amounts in CTLs and severely impairs
their activation, expansion, and effector differentiation during a
primary antiviral response.
IL-33 Is Dispensable for CD8+ T Cell
Memory Formation and Maintenance
To assess whether a lack of IL-33 during priming affects the
formation of memory CTLs, we adoptively transferred LCMV-
specific CD8+ T cells (P14 cells) either into WT or IL-33-
deficient primary recipient mice, followed by infection with 200
PFU LCMV. After 16 days, when clearance of such a low-dose
LCMV infection can be assumed (16), the progeny of these
CTLs were isolated again and equal numbers were re-transferred
into naive WT secondary recipients (Figure 3A). Time course
analyses from blood revealed that both CTL populations were
maintained similarly (Figure 3B) and upregulated CD127 and
CD62L comparably over time (Figure 3C). When restimulated
with peptide on day 65 after second transfer, the production of
IFN-γ, either alone or in combination with TNF-α and IL-2, was
comparable in both CTL populations (Figure 3D). Furthermore,
the expression levels of T-bet and Eomes by splenic P14 cells were
virtually identical (Figure 3E). These data indicate that the lack of
IL-33 during the priming phase does neither impair the memory
differentiation of effector CTLs nor their maintenance over time.
Yet, we wondered whether withdrawal of IL-33 signals during
the memory phase impairs CTL maintenance. For this, P14
cells were transferred into primary WT hosts, primed by LCMV
infection, and then re-transferred into WT or Il33−/− secondary
recipients (Figure 3F). Again, the maintenance of both CTL
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FIGURE 2 | IL-33 enhances CD8+ T cell activation and differentiation during a primary viral infection. (A–E) WT and Il1rl1−/− mice were infected with a low dose (LD,
200 PFU) LCMV-WE and spleens were analyzed at day 6.5 after infection (n = 5). (A) Frequency of CD8+ T cells among lymphocytes. Frequency (B) and absolute
numbers (C) of splenic CD44hi CD62Llo effector CD8+ T cells. Total count of GP33-and NP396-tetramer+ CD8+ T cells per spleen (D) and frequency of KLRG1+
and CXCR3+ cells among NP396-tetramer+ CD8+ T cells (E). (F–L) Naive Il1rl1+/+ and Il1rl1−/− P14 cells were transferred into WT recipients. Recipients were
subsequently infected with a low dose (LD, 200 PFU) LCMV-WE. P14 cells from spleen and lymph nodes were analyzed at day 6.5 after infection (n = 5–6).
Frequencies of KLRG1+ (F), CXCR3+ (G), and CD127+ (H) cells among CD45.1+ P14 cells. Expression levels of T-bet (I) and IL-18R (J) of CD45.1+ P14T cells
plotted as geometric mean (GM) of fluorescence intensity. Representative histogram (K) and quantification (L) of IFN-γ production by Il1rl1+/+ and Il1rl1−/− P14 cells
after restimulation with GP33 peptide (black histogram: unstimulated Il1rl1+/+ P14 cells). (M,N) WT and Il1rl1−/− mice were infected with a low dose (LD, 200 PFU)
LCMV-WE. Spleen and lymph nodes were analyzed after GP33 peptide restimulation at day 6.5 post infection. (M) Frequencies of cytokine-producing GP33-specific
CD44hi CD8+ T cells and a representative FACS plot of IFN-γ and TNF-α expression (N) by CD44hi CD8+ T cells. Bars indicate the mean + SD (n = 3). P-values
were calculated with unpaired two-tailed Student’s t-test. *P < 0.05, **P < 0.01, and ***P < 0.001.
populations (Figure 3G) and their CD62L and CD127 profiles
(Figure 3H) were indistinguishable for >200 days. Also, their
cytokine production upon peptide restimulation (Figure 3I) and
the expression of T-bet and Eomes (Figure 3J) were comparable.
This shows that IL-33 is neither required for CTL memory
formation nor maintenance.
Lack of IL-33 During Priming Does Not
Impair Memory CTL Protection Against
Viral Reinfection
Next, we asked whether a lack of IL-33 signals during
CTL priming, causing reduced peak expansion and effector
differentiation in the primary response (cf. Figure 2), would
translate into durable cell-intrinsic defects. These effects could
then manifest in a defective secondary antiviral response even
when tested in an IL-33-competent environment (Figure 4A).
When adoptively transferred into WT secondary hosts, memory
P14 cells derived from WT or Il33−/− primary recipients
expanded to similar frequencies and total numbers after LCMV
challenge infection (Figure 4B). Moreover, P14 cells from both
groups exhibited comparable expression of the cell surface
receptors KLRG1, CXCR3, CD127, and ST2 (Figure 4C). While
the formerly IL-33-deprived P14 cells produced slightly less
IFN-γ and TNF-α after peptide restimulation (Figure 4D),
the expression levels of T-bet and Eomes were comparable
(Figure 4E). Functionally, the minor differences in cytokine
production between the two P14 CTL populations did not
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FIGURE 3 | IL-33 is dispensable for CD8+ T cell memory formation and maintenance. (A) Schematic experimental layout to assess IL-33 signals during memory
formation in (B–E). (B) Frequency of P14 cells in the blood of WT recipients at the indicated time points after secondary transfer. (C) Frequency of CD62Lhi CD127+
cells within the P14 cell subset. Symbols of the time course analyses represent mean ± SD (n = 4) of one representative experiment out of three performed. (D) After
65 days, recipients were sacrificed. Cytokine production of splenic P14 cells after GP33 restimulation. (E) Expression levels of T-bet and Eomes by splenic P14 cells
(geometric mean index, normalized to isotype). (F) Schematic experimental layout to assess IL-33 signals during memory maintenance in (G–J). (G) Frequency of
transferred P14 cells in the blood of secondary recipients and absolute numbers of P14 cells in the spleen at day 65 post second transfer (insert panel). (H) Frequency
of CD62Lhi CD127+ cells within the P14 cell subset. Symbols of the time course analyses represent mean ± SD (n = 5) of one out of two experiments with similar
results. (I) After 65 days, recipients were sacrificed in some experiments. Cytokine production by splenic P14 cells after GP33 peptide restimulation. (J) Expression
levels of T-bet and Eomes by P14 cells (geometric mean index, normalized to isotype). Symbols represent single mice, the bars the mean + SD. P-values were
calculated with unpaired two-tailed Student’s t-test [starting-point-normalized Area under the curve (AUC) in (B,G), AUC in (C,H)]. *P < 0.05.
translate into differential viral clearance. When compared to
mice without P14 cell transfer, viral titers in spleen, liver, lung,
and kidney were reduced to a similar extent irrespective of the
source of memory P14 cells transferred (Figure 4F). In summary,
memory CTLs emerging from an IL-33-deprived environment
were fully functional and protective, and displayed a largely
normal phenotype upon secondary infection.
Memory CTLs Require IL-33 for a
Protective Antiviral Recall Response
During primary infection, IL-33 enhances the response of naive
CD8+ T cells (cf. Figure 2) and is necessary for virus control
(16). Thus, we wondered whether the antiviral recall response
of an established CTL memory population still depends on
IL-33 signals. To address this, adoptively transferred naive
P14 cells were primed with LCMV in WT primary recipients.
The resulting P14 memory cells were then adoptively re-
transferred intoWTor Il33−/− secondary hosts andwere allowed
to rest for 65 days to ensure, to the extent possible, their
memory differentiation prior to LCMV re-challenge infection
(Figure 5A). The expansion of P14 memory cells was >10-
fold reduced when the cells were challenged in IL-33-deficient
recipients as opposed to WT hosts (Figure 5B). Moreover, P14
cells in Il33−/− mice showed a less activated effector phenotype,
as evident in lower KLRG1 and CXCR3 expression and higher
expression of CD62L (Figures 5C,D). In line with this, the
expression of IFN-γ and TNF-α upon peptide restimulation
was impaired in Il33−/− hosts (Figure 5E). Beyond the lower
frequency of cytokine+ CTLs, the average amounts of IFN-γ
produced by IFN-γ-positive cells were also reduced (Figure 5F).
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FIGURE 4 | Lack of IL-33 during priming does not impair protection by memory CTLs upon viral reinfection. (A) Schematic experimental layout to assess the impact
of IL-33 signals during priming on the outcome of a challenge infection. (B) Frequency and total P14 cell numbers in the spleen. (C) Expression of cell-surface markers
by splenic P14 cells. (D) Cytokine production by P14 cells in the spleen after GP33 restimulation. (E) Expression levels of T-bet and Eomes by P14 cells (geometric
mean index, normalized to isotype). (F) Viral titers in the organs indicated. Bar graphs in (B–E) show the mean + SD (n = 4). Symbols in F represent single mice, the
bars the median. Each experiment was performed two to three times. P-values were calculated with unpaired two-tailed Student’s t-test (B–E) and Mann-Whitney U
test (F). *P < 0.05 and **P < 0.01.
As compared to their naive counterparts, memory CTLs are
more efficient in controlling a challenge infection (4). Indeed,
when we compared WT mice with and without P14 cell
transfer, we found that P14 memory cells potently suppressed
viral replication (Figure 5G). In contrast, P14 memory cells
in Il33−/− hosts contributed little, if any, to viral control
(Figure 5G). While memory P14 cells reduced viral loads
in WT recipient spleens 170-fold, no more than a two-fold
reduction resulted when the same cells were transferred to
Il33−/− recipients. This reflected a drastic improvement of
memory CTL-mediated virus control in IL-33-competent mice
(Figure 5H). Thus, memory CTLs need IL-33 in an antiviral
recall response for efficient re-expansion, effector differentiation,
and protection.
DISCUSSION
Both naive and memory CD8+ T cells require cytokines as
co-factors for their activation, yet their specific demands differ
(8, 9, 32). The alarmin IL-33 was shown to enhance primary
CTL responses, but the molecular regulation of IL-33 receptor
expression and the impact of IL-33 signals on an antiviral recall
response of memory CTLs remained ill-defined. In our study, we
showed that expression of the IL-33 receptor ST2 on CTLs largely
depends on STAT4 and to some extent also on IL-12. While IL-33
signals enhance antiviral CTL effector differentiation in a primary
response, the formation and maintenance of memory CTLs were
independent of IL-33. Conversely, memory CTLs required IL-33
for a protective antiviral recall response.
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FIGURE 5 | Memory CTLs require IL-33 for a protective antiviral recall response. (A) Schematic experimental layout to study the role of IL-33 during a recall response.
(B) Total numbers of P14 cells in spleen and liver. (C) Expression of surface markers by P14 cells from spleen and liver. (D) Representative FACS plots of CXCR3 and
KLRG1 expression by splenic P14 cells. Average geometric means of CXCR3 (top) and KLRG1 (bottom) ± SD are depicted in gray. (E) Cytokine production by P14
cells from spleen and liver after GP33 restimulation. (F) Expression levels of IFN-γ by IFN-γ+ P14 cells in spleen and liver. (G) Viral titers in the organs indicated.
Symbols in (H) represent single mice, the bars the median. (H) Factors of enhanced viral clearance by memory P14 cells were calculated by dividing the median viral
load of mice without cell transfer by the median viral load of mice with P14 cell transfer. Bar graphs in (B–G) indicate the mean + SD (n = 5). Each experiment was
performed twice. P-values were calculated with unpaired two-tailed Student’s t-test (B,C,E,F) and Mann-Whitney U test (G). *P < 0.05, **P < 0.01, and ***P < 0.001.
Activated STAT4 plays a critical role in chromatin
modification and gene expression (33) and is increased in CTLs
responding to an LCMV infection (34). In CD4+ T cells, STAT4
induces ST2 expression together with T-bet (35, 36), possibly due
to the ability of STAT4 and/or T-bet to open the ST2-encoding
gene locus Il1rl1 in the context of T cell effector differentiation
(33). This is in line with our findings of STAT4-dependent ST2
expression in CTLs. It remains unclear whether the STAT4
effect is mediated directly or indirectly, e.g., by promoting T-bet
expression. STAT4 phosphorylation is prominently mediated by
IL-12 (37), but also by type-I IFNs, which upon LCMV infection
are released in much higher amounts than IL-12 (38). Thus, we
assume that type-I IFN-triggered STAT4 activation can partially
compensate for the lack of IL-12, explaining why defective ST2
expression is more prominent in Stat4−/− CTLs than in those
of Il12p40−/− mice. Yet, STAT4 deficiency did not completely
abrogate ST2 expression in vivo. CD8+ T cells, albeit at a low
level, express the transcription factor GATA-3, which has been
shown to regulate ST2 expression in Th2 cells, and its absence
compromises the expansion of virus-specific CD8+ T cells in an
acute LCMV infection (39). It is conceivable that in the absence
of STAT4, residual ST2 expression might be driven by GATA-3.
While primary CTL responses are enhanced by IL-33,
formation of circulating memory CD8+ T cell was fully
supported in a IL-33-deficient environment. Likewise, the
maintenance of memory CTLs is independent of IL-33 signals.
This is consistent with the transient and activation-dependent
nature of ST2 expression on CTLs. Absence of ST2 expression
on circulating CD8+ T cells during memory formation and
maintenance might help preventing the undesired activation
of CTLs in the absence of cognate antigen. The possibility
to selectively act on activated CD8+ T cells in a very short
time frame during the effector phase distinguishes IL-33 from
other cytokines such as IL-7 and IL-15, which provide signals
for memory CTL homeostatic proliferation and population
maintenance (2, 3). It has been reported that IL-2 plays
an important role during primary infection in programming
the development of memory CTLs to ensure full secondary
expansion upon challenge (8). IL-33 and IL-2 exhibit functional
similarities in their capacity to enhance primary CTL responses.
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Yet, the absence of IL-33 signals during CTL priming did not
phenocopy the IL-2-deprived “helpless” memory CTL, and a
defective primary effector T cell differentiation did not translate
into a permanent cell-intrinsic impairment. On the contrary,
CTL priming in the absence of IL-33 still allowed for protective
memory CTL recall responses provided the cells were challenged
in an IL-33-sufficient environment.
During a recall response, memory CTLs re-expressed ST2
and required IL-33 for efficient reactivation and virus control.
Notably, ST2 expression levels were identical between CD8+
memory cells reactivated in Il33−/− or WT mice, indicating
that ST2 expression in antiviral CTLs is independent of IL-
33 signals. In memory Th2 cells and regulatory T cells, ST2
expression depends on the transcription factor GATA-3, and
IL-33 signaling can induce GATA-3 phosphorylation (40–42).
This suggests a positive feedback loop, in which IL-33 binding
to its receptor ST2 elicits GATA-3 phosphorylation, which
in turn can lead to nuclear translocation of GATA-3 and
enhancement of ST2 expression (15). This mechanism could
explain the increase of ST2 expression by IL-33 in memory
Th2 cells (42). In contrast, our results show that in CD8+ T
cells, ST2 expression is to a large extent dependent on the
transcription factor STAT4. So far, there is no evidence that
IL-33 signaling can modulate STAT4 activity, implying a lack
of positive feedback mechanisms affecting ST2 expression in
CD8+ T cells. Similar to IL-33 effects in the primary response,
the selective expression of ST2 on activated CD8+ memory
T cells may facilitate the preferential secondary expansion of
antigen-specific circulating effector cells. Additionally, IL-33
enhances effector differentiation and boosts cytokine production
at a single cell level, thus acting in a multi-tiered process
to achieve efficient virus control. This finding is in line with
the notion of IL-33 as an alarmin—an early damage signal
that activates innate and adaptive immune cells (43, 44). It
is surprising though that also memory cells, which have an
advanced differentiation state and respond faster than naive cells
(45, 46), require IL-33 to unleash their full protective potential.
Thereby, IL-33 can fine tune both primary and secondary
immune responses based on the magnitude of its cell damage-
associated release.
Our experimental setup of adoptive CD8+ T cell transfers
betweenWT and IL-33-deficient mice (and vice versa) allowed us
to deprive CTLs of IL-33 signals selectively during different stages
of their differentiation. In contrast to a transfer of ST2-deficient
P14 cells, this approach enabled us to address the relevance
of IL-33 signals during memory formation, maintenance, and
re-challenge without compromising the primary activation of
these LCMV-specific CD8+ T cells. However, this experimental
strategy has its limitations as it levels out numerical differences
between CTLs primed in the presence or absence of IL-33. Such
differences in cell numbers, albeit minor (16), might still affect
the outcome of a secondary response. This was shown in a
vaccination study utilizing IL-33 DNA constructs to increase the
size of the CTL memory pool (47). Moreover, the requirement
for IL-33 signals might differ between circulating and tissue-
resident memory T cells (TRM). It was shown recently that IL-
33 signals are essential for inflationary expansion of CD8+ TRM
in a chronic cytomegalovirus infection (48). Our experimental
approach of transferring equal numbers of P14 CD8+ T cells
into IL-33-deficient or -sufficient recipient mice was chosen to
study the role of IL-33 in a cell-intrinsic manner. Still, the
theoretical possibility remains that ST2-expressing cells other
than CD8+ T cells contribute to the phenotypes observed or
that the lack of IL-33 indirectly affects the antiviral immune
response by altering various other immune compartments under
homeostatic conditions. In fact, the lack of IL-33 has been
shown to dampen the local activation of type 2 innate lymphoid
cells (ILC2s), already in the steady state (49–51). It therefore is
conceivable that IL-33may affect the homeostasis of conventional
ILC1s or natural killer cells, which can contribute to antiviral
immune responses (52, 53). Nevertheless, we consider it highly
unlikely that such alterations would have substantial effects
on the parameters studied here. First, it is well established
that acute viral clearance in the LCMV challenge model is
virtually exclusively mediated by CD8+ T cells (54). Second, our
previous work using both adoptive T cell transfer and bone-
marrow chimera experiments established that IL-33 augments
antiviral responses by acting directly on ST2-expressing CTLs
(16). In conclusion, our findings reveal an unexpected role
of alarmins as important co-factors in antiviral CTL recall
responses. Hence, the manipulation of alarmin signals such as IL-
33 may offer opportunities for improved therapies of recurrent
viral diseases.
DATA AVAILABILITY
All datasets generated for this study are included in the
manuscript and/or the supplementary files.
ETHICS STATEMENT
Animal protocols were performed in accordance with the
German law for animal protection and the institutional
guidelines of the Charité Berlin. All experiments were approved
by the Landesamt für Gesundheit und Soziales in Berlin
(LAGeSO, approval number G 0242/12).
AUTHOR CONTRIBUTIONS
CB, AF, TB, DP, and ML designed the research. CB, AF, TB, and
VH performed the research. CB, AF, and TB analyzed the data.
CB and ML wrote the paper.
FUNDING
This work was supported by the German Research Foundation
(SFB650, grant TP28, and grant LO 1542/3-1 to ML), the Swiss
National Science Foundation (Sinergia grant CRSII3_160772/1
to DP and ML), Volkswagen Foundation (Lichtenberg Program
to ML), and Willy Robert Pitzer Foundation (Osteoarthritis
Research Program to ML). CB and TB were fellows of the
InternationalMax Planck Research School for Infectious Diseases
and Immunology.
Frontiers in Immunology | www.frontiersin.org 9 August 2019 | Volume 10 | Article 1833
Baumann et al. IL-33 Drives Memory CTL Reactivation
ACKNOWLEDGMENTS
We thank S. Ebel, P. Wu, and C. Rüster for expert technical
assistance, J. Siede and S. Kallert for experimental help, and
A.N. Hegazy and R.M. Marek for helpful discussion and
comments on the manuscript. Cell sorting was carried out
at the Flow Cytometry Core Facility at the DRFZ. Il1rl1−/−
mice were obtained under MTA from A. McKenzie (MRC,
Cambridge, UK) and P. Fallon (Trinity College Dublin,
Ireland). Il33−/− mice were obtained under MTA from
S. Nakae and H. Saito (University of Tokyo, Japan). We
acknowledge support from the German Research Foundation
(DFG) and the Open Access Publication Fund of Charité-
Universitätsmedizin Berlin.
REFERENCES
1. Ahmed R, Gray D. Immunological memory and protective
immunity: understanding their relation. Science. (1996) 272:54–
60. doi: 10.1126/science.272.5258.54
2. Schluns KS, KieperWC, Jameson SC, Lefrancois L. Interleukin-7 mediates the
homeostasis of naive and memory CD8T cells in vivo. Nat Immunol. (2000)
1:426–32. doi: 10.1038/80868
3. Becker TC, Wherry EJ, Boone D, Murali-Krishna K, Antia R, Ma A,
et al. Interleukin 15 is required for proliferative renewal of virus-specific
memory CD8T cells. J Exp Med. (2002) 195:1541–8. doi: 10.1084/jem.2002
0369
4. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation:
implications for vaccine development. Nat Rev Immunol. (2002) 2:251–
62. doi: 10.1038/nri778
5. Kim SK, Schluns KS, Lefrancois L. Induction and visualization of mucosal
memory CD8T cells following systemic virus infection. J Immunol.
(1999) 163:4125–32.
6. Ariotti S, HogenbirkMA, Dijkgraaf FE, Visser LL, HoekstraME, Song JY, et al.
T cell memory. Skin-resident memory CD8+ T cells trigger a state of tissue-
wide pathogen alert. Science. (2014) 346:101–5. doi: 10.1126/science.1254803
7. Schenkel JM, Fraser KA, Beura LK, Pauken KE, Vezys V, Masopust D. T
cell memory. Resident memory CD8T cells trigger protective innate and
adaptive immune responses. Science. (2014) 346:98–101. doi: 10.1126/science.
1254536
8. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are
required for secondary expansion of CD8+ memory T cells. Nature. (2006)
441:890–3. doi: 10.1038/nature04790
9. Ma C, Zhang N. Transforming growth factor-beta signaling is constantly
shaping memory T-cell population. Proc Natl Acad Sci USA. (2015)
112:11013–7. doi: 10.1073/pnas.1510119112
10. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, Mcclanahan TK, et al.
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related
protein ST2 and induces T helper type 2-associated cytokines. Immunity.
(2005) 23:479–90. doi: 10.1016/j.immuni.2005.09.015
11. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-
33 is constitutively expressed in the nucleus of endothelial cells
and epithelial cells in vivo: a novel ‘alarmin’? PLoS ONE. (2008)
3:e3331. doi: 10.1371/journal.pone.0003331
12. Kallert SM, Darbre S, Bonilla WV, Kreutzfeldt M, Page N, Muller P,
et al. Replicating viral vector platform exploits alarmin signals for potent
CD8+ T cell-mediated tumour immunotherapy. Nat Commun. (2017)
8:15327. doi: 10.1038/ncomms15327
13. Palmer G, Gabay C. Interleukin-33 biology with potential insights into human
diseases. Nat Rev Rheumatol. (2011) 7:321–9. doi: 10.1038/nrrheum.2011.53
14. Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat
Rev Immunol. (2016) 16:676–89. doi: 10.1038/nri.2016.95
15. Peine M, Marek RM, Lohning M. IL-33 in T cell differentiation,
function, and immune homeostasis. Trends Immunol. (2016) 37:321–
33. doi: 10.1016/j.it.2016.03.007
16. Bonilla WV, Frohlich A, Senn K, Kallert S, Fernandez M, Johnson S,
et al. The alarmin interleukin-33 drives protective antiviral CD8+
T cell responses. Science. (2012) 335:984–9. doi: 10.1126/science.12
15418
17. Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and
enhanced development of Th2 cells in Stat4-deficient mice. Nature. (1996)
382:174–7. doi: 10.1038/382174a0
18. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher
LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-
gamma production in CD4 and CD8T cells. Science. (2002) 295:338–
42. doi: 10.1126/science.1065543
19. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al.
Functional role of type I and type II interferons in antiviral defense. Science.
(1994) 264:1918–21. doi: 10.1126/science.8009221
20. Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu CY,
Ferrante J, et al. IL-12-deficient mice are defective in IFN gamma
production and type 1 cytokine responses. Immunity. (1996)
4:471–81. doi: 10.1016/S1074-7613(00)80413-6
21. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R, et al.
Immune response in mice that lack the interferon-gamma receptor. Science.
(1993) 259:1742–5. doi: 10.1126/science.8456301
22. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, Mckenzie AN. T1/ST2-
deficient mice demonstrate the importance of T1/ST2 in developing
primary T helper cell type 2 responses. J Exp Med. (2000) 191:1069–
76. doi: 10.1084/jem.191.6.1069
23. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the
mouse Stat1 gene results in compromised innate immunity to viral disease.
Cell. (1996) 84:443–50. doi: 10.1016/S0092-8674(00)81289-1
24. Pircher H, Bürki K, Lang R, Hengartner H, Zinkernagel RM. Tolerance
induction in double specific T-cell receptor transgenic mice varies with
antigen. Nature. (1989) 342:559–61. doi: 10.1038/342559a0
25. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, et al. IL-33 is a
crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci
USA. (2010) 107:18581–6. doi: 10.1073/pnas.1003059107
26. Battegay M, Cooper S, Althage A, Banziger J, Hengartner H, Zinkernagel RM.
Quantification of lymphocytic choriomeningitis virus with an immunological
focus assay in 24- or 96-well plates. J Virol Methods. (1991) 33:191–
8. doi: 10.1016/0166-0934(91)90018-U
27. Yang Q, Li G, Zhu Y, Liu L, Chen E, Turnquist H, et al. IL-33 synergizes with
TCR and IL-12 signaling to promote the effector function of CD8+ T cells.
Eur J Immunol. (2011) 41:3351–60. doi: 10.1002/eji.201141629
28. Holz A, Bot A, Coon B, Wolfe T, Grusby MJ, Von Herrath MG. Disruption
of the STAT4 signaling pathway protects from autoimmune diabetes while
retaining antiviral immune competence. J Immunol. (1999) 163:5374–82.
29. Oxenius A, Karrer U, Zinkernagel RM, Hengartner H. IL-12 is not required
for induction of type 1 cytokine responses in viral infections. J Immunol.
(1999) 162:965–73.
30. Taqueti VR, Grabie N, Colvin R, Pang H, Jarolim P, Luster AD,
et al. T-bet controls pathogenicity of CTLs in the heart by separable
effects on migration and effector activity. J Immunol. (2006) 177:5890–
901. doi: 10.4049/jimmunol.177.9.5890
31. Joshi NS, Cui W, Chandele A, Lee HK, Urso DR, Hagman J, et al.
Inflammation directs memory precursor and short-lived effector CD8+ T cell
fates via the graded expression of T-bet transcription factor. Immunity. (2007)
27:281–95. doi: 10.1016/j.immuni.2007.07.010
32. Bachmann MF, Wolint P, Walton S, Schwarz K, Oxenius A. Differential role
of IL-2R signaling for CD8+ T cell responses in acute and chronic viral
infections. Eur J Immunol. (2007) 37:1502–12. doi: 10.1002/eji.200637023
33. Wei L, Vahedi G, Sun HW, Watford WT, Takatori H, Ramos HL,
et al. Discrete roles of STAT4 and STAT6 transcription factors in tuning
epigeneticmodifications and transcription during T helper cell differentiation.
Immunity. (2010) 32:840–51. doi: 10.1016/j.immuni.2010.06.003
34. Gil MP, Ploquin MJ, Watford WT, Lee SH, Kim K, Wang X, et al.
Regulating type 1 IFN effects in CD8T cells during viral infections:
Frontiers in Immunology | www.frontiersin.org 10 August 2019 | Volume 10 | Article 1833
Baumann et al. IL-33 Drives Memory CTL Reactivation
changing STAT4 and STAT1 expression for function. Blood. (2012) 120:3718–
28. doi: 10.1182/blood-2012-05-428672
35. Baumann C, Bonilla WV, Frohlich A, Helmstetter C, Peine M, Hegazy
AN, et al. T-bet- and STAT4-dependent IL-33 receptor expression directly
promotes antiviral Th1 cell responses. Proc Natl Acad Sci USA. (2015)
112:4056–61. doi: 10.1073/pnas.1418549112
36. Alvarez F, Fritz JH, Piccirillo CA. Pleiotropic effects of IL-33 on CD4+
T cell differentiation and effector functions. Front Immunol. (2019)
10:522. doi: 10.3389/fimmu.2019.00522
37. Jacobson NG, Szabo SJ, Weber-Nordt RM, Zhong Z, Schreiber RD, Darnell
JEJr, et al. Interleukin 12 signaling in T helper type 1 (Th1) cells involves
tyrosine phosphorylation of signal transducer and activator of transcription
(Stat)3 and Stat4. J Exp Med. (1995) 181:1755–62. doi: 10.1084/jem.181.5.
1755
38. Hegazy AN, Peine M, Helmstetter C, Panse I, Frohlich A, Bergthaler A, et al.
Interferons direct Th2 cell reprogramming to generate a stable GATA-3+T-
bet+ cell subset with combined Th2 and Th1 cell functions. Immunity. (2010)
32:116–28. doi: 10.1016/j.immuni.2009.12.004
39. Wang Y, Misumi I, Gu AD, Curtis TA, Su L, Whitmire JK, et al. GATA-3
controls the maintenance and proliferation of T cells downstream of TCR and
cytokine signaling. Nat Immunol. (2013) 14:714–22. doi: 10.1038/ni.2623
40. Hayakawa M, Yanagisawa K, Aoki S, Hayakawa H, Takezako N, Tominaga
S. T-helper type 2 cell-specific expression of the ST2 gene is regulated
by transcription factor GATA-3. Biochim Biophys Acta. (2005) 1728:53–
64. doi: 10.1016/j.bbaexp.2005.01.012
41. Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert
EA, et al. The alarmin IL-33 promotes regulatory T-cell function in the
intestine. Nature. (2014) 513:564–8. doi: 10.1038/nature13577
42. Endo Y, Hirahara K, Iinuma T, Shinoda K, Tumes DJ, Asou
HK, et al. The interleukin-33-p38 kinase axis confers memory
T helper 2 cell pathogenicity in the airway. Immunity. (2015)
42:294–308. doi: 10.1016/j.immuni.2015.01.016
43. Oppenheim JJ, Yang D. Alarmins: chemotactic activators
of immune responses. Curr Opin Immunol. (2005) 17:359–
65. doi: 10.1016/j.coi.2005.06.002
44. Garlanda C, Dinarello CA,Mantovani A. The interleukin-1 family: back to the
future. Immunity. (2013) 39:1003–18. doi: 10.1016/j.immuni.2013.11.010
45. Zimmermann C, Prevost-Blondel A, Blaser C, Pircher H. Kinetics of the
response of naive and memory CD8T cells to antigen: similarities and
differences. Eur J Immunol. (1999) 29:284–90.
46. Veiga-Fernandes H, Walter U, Bourgeois C, Mclean A, Rocha B. Response of
naive and memory CD8+ T cells to antigen stimulation in vivo. Nat Immunol.
(2000) 1:47–53. doi: 10.1038/76907
47. Villarreal DO, Weiner DB. Interleukin 33: a switch-hitting cytokine. Curr
Opin Immunol. (2014) 28:102–6. doi: 10.1016/j.coi.2014.03.004
48. McLaren JE, ClementM,MarsdenM,Miners KL, Llewellyn-Lacey S, Grant EJ,
et al. IL-33 augments virus-specificmemory T cell inflation and potentiates the
efficacy of an attenuated cytomegalovirus-based vaccine. J Immunol. (2019)
202:943–55. doi: 10.4049/jimmunol.1701757
49. Brestoff JR, Kim BS, Saenz SA, Stine RR, Monticelli LA, Sonnenberg GF, et al.
Group 2 innate lymphoid cells promote beiging of white adipose tissue and
limit obesity. Nature. (2015) 519:242–6. doi: 10.1038/nature14115
50. Lee MW, Odegaard JI, Mukundan L, Qiu Y, Molofsky AB, Nussbaum JC,
et al. Activated type 2 innate lymphoid cells regulate beige fat biogenesis. Cell.
(2015) 160:74–87. doi: 10.1016/j.cell.2014.12.011
51. Molofsky AB, Van Gool F, Liang HE, Van Dyken SJ, Nussbaum JC, Lee J,
et al. Interleukin-33 and interferon-gamma counter-regulate group 2 innate
lymphoid cell activation during immune perturbation. Immunity. (2015)
43:161–74. doi: 10.1016/j.immuni.2015.05.019
52. Freeman BE, Raue HP, Hill AB, Slifka MK. Cytokine-mediated
activation of NK cells during viral infection. J Virol. (2015)
89:7922–31. doi: 10.1128/JVI.00199-15
53. Weizman OE, Adams NM, Schuster IS, Krishna C, Pritykin Y, Lau C, et al.
ILC1 confer early host protection at initial sites of viral infection. Cell. (2017)
171:795–808.e712. doi: 10.1016/j.cell.2017.09.052
54. Fung-Leung WP, Kundig TM, Zinkernagel RM, Mak TW. Immune response
against lymphocytic choriomeningitis virus infection in mice without CD8
expression. J Exp Med. (1991) 174:1425–9. doi: 10.1084/jem.174.6.1425
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Baumann, Fröhlich, Brunner, Holecska, Pinschewer and Löhning.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Immunology | www.frontiersin.org 11 August 2019 | Volume 10 | Article 1833
